Abbott noted that the Amplatzer Piccolo, a device even smaller than a small pea, now offers hope to premature infants and newborns who need corrective treatment, and who may be non-responsive to ...

The US Food and Drug Administration (FDA) has approved the Amplatzer Piccolo Occluder (Abbott), the first medical device to treat patent ductus arteriosus (PDA) in premature babies weighing as little ...

Abbott’s range of entries to Fast Company’s 2o20 World Changing Ideas Awards made it our selection for World Changing Company of the Year. While the company is currently a major player in helping ramp ...

Add Yahoo as a preferred source to see more of our stories on Google. Abbott laboratories in Sunnyvale, Calif., on Aug. 24, 2019. Abbott said last week that it has received clearance to sell a device ...

First and only delivery system designed specifically for premature infants with a patent ductus arteriosus (PDA), a life-threatening opening in their heart New delivery system enables precise ...

Results reinforce that Amplatzer Piccolo™ Occluder is safe and effective for closing an opening in the heart known as a "patent ductus arteriosus" (PDA) in newborns Study found low adverse event rates ...

Add Yahoo as a preferred source to see more of our stories on Google. Abbott’s range of paediatric heart treatments also includes the Masters HP 15mm mechanical heart valve. Credit: Michael Vi / ...

Chicago-based Abbott Laboratories received an FDA approval for the Amplatzer Piccolo Occluder to treat patent ductus arteriosus (PDA), a condition in which a newborn has a persistent opening in the ...

A PDA requiring treatment is present in approximately 20% of premature infants 1 ABBOTT PARK, Ill., Dec. 18, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug ...